AbbVie (NYSE:ABBV) Issues FY 2026 Earnings Guidance

AbbVie (NYSE:ABBV) updated its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 13.950-13.990 for the period, compared to the consensus estimate of 13.950. The company issued revenue guidance of $67.8 billion, compared to the consensus revenue estimate of $67.6 billion. AbbVie also updated its Q4 2026 guidance to 3.830-3.870 EPS.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on ABBV shares. Barclays raised their target price on shares of AbbVie from $300.00 to $325.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 21st. Oppenheimer upped their price target on shares of AbbVie from $244.00 to $258.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. Canaccord Genuity Group upped their price target on shares of AbbVie from $290.00 to $338.00 and gave the company a “buy” rating in a research report on Monday. Royal Bank Of Canada increased their price target on shares of AbbVie from $280.00 to $330.00 and gave the stock an “outperform” rating in a research note on Monday. Finally, Cantor Fitzgerald raised their price objective on shares of AbbVie from $290.00 to $325.00 and gave the stock an “overweight” rating in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $296.88.

AbbVie Stock Down 1.0%

Shares of ABBV stock opened at $285.88 on Wednesday. The stock’s 50-day moving average price is $270.23 and its 200 day moving average price is $237.89. The stock has a market capitalization of $505.09 billion, a PE ratio of 49.20, a price-to-earnings-growth ratio of 1.31 and a beta of 0.20. AbbVie has a 52-week low of $190.75 and a 52-week high of $298.74.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, October 30th. The company reported $3.82 earnings per share for the quarter, topping analysts’ consensus estimates of $3.73 by $0.09. AbbVie had a negative return on equity of 435.41% and a net margin of 15.67%. The company had revenue of $17.40 billion during the quarter, compared to analysts’ expectations of $17.32 billion. During the same period last year, the firm earned $1.86 EPS. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. Analysts expect that AbbVie will post 14.00 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 16th. Stockholders of record on Friday, January 15th will be paid a dividend of $1.82 per share. This represents a $7.28 annualized dividend and a dividend yield of 2.5%. This is a boost from AbbVie’s previous quarterly dividend of $1.73. The ex-dividend date is Friday, January 15th. AbbVie’s dividend payout ratio (DPR) is currently 119.10%.

Insider Activity at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.06% of the stock is owned by company insiders.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie signed a global license deal for Nxera Pharma’s investigational oral EP4 agonist for inflammatory bowel disease. The agreement includes $100 million upfront, up to $1.37 billion in contingent development and commercial milestones, and royalties. It adds potential pipeline value, though payments beyond the upfront fee depend on development and commercial success. Nxera Pharma license agreement with AbbVie
• Positive Sentiment: Several analysts raised their price targets and maintained positive ratings following AbbVie’s recent results, adding support to the view that earnings growth and its newer medicines can sustain momentum. Morgan Stanley raises AbbVie price target
• Positive Sentiment: AbbVie raised its 2026 outlook, with full-year revenue guidance of $67.8 billion above the cited consensus of $67.6 billion. Recent quarterly results also showed revenue growth, while Skyrizi and Rinvoq are helping offset Humira’s decline. AbbVie Q3 results and growth drivers
• Neutral Sentiment: AbbVie expanded its Oxford R&D facility as part of an investment exceeding £120 million. The expansion supports research capacity over time, but does not indicate an immediate revenue contribution. AbbVie expands Oxford R&D facility
• Negative Sentiment: AbbVie is abandoning a Phase 2 solid-tumor drug program after seeing “limited benefit,” a setback for its oncology pipeline. Fourth-quarter EPS guidance of $3.83–$3.87 also falls short of the cited $3.89 consensus, despite revenue guidance slightly above estimates. AbbVie discontinues Phase 2 solid-tumor drug

About AbbVie

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.